Biosimilars: what clinicians should know
Top Cited Papers
Open Access
- 20 December 2012
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 120 (26), 5111-5117
- https://doi.org/10.1182/blood-2012-04-425744
Abstract
Biosimilar medicinal products (biosimilars) have become a reality in the European Union and will soon be available in the United States. Despite an established legal pathway for biosimilars in the European Union since 2005 and increasing and detailed regulatory guidance on data requirements for their development and licensing, many clinicians, particularly oncologists, are reluctant to consider biosimilars as a treatment option for their patients. Major concerns voiced about biosimilars relate to their pharmaceutical quality, safety (especially immunogenicity), efficacy (particularly in extrapolated indications), and interchangeability with the originator product. In this article, the members and experts of the Working Party on Similar Biologic Medicinal Products of the European Medicines Agency (EMA) address these issues. A clear understanding of the scientific principles of the biosimilar concept and access to unbiased information on licensed biosimilars are important for physicians to make informed and appropriate treatment choices for their patients. This will become even more important with the advent of biosimilar monoclonal antibodies. The issues also highlight the need for improved communication between physicians, learned societies, and regulators.Keywords
This publication has 26 references indexed in Scilit:
- Tungsten-Induced Denaturation and Aggregation of Epoetin Alfa During Primary Packaging as a Cause of ImmunogenicityPharmaceutical Research, 2011
- Biosimilars of Biological Drug TherapiesDrugs, 2011
- Concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilization of stem cells in normal donors: position of the World Marrow Donor AssociationHaematologica, 2011
- Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow TransplantationHaematologica, 2011
- Biosimilar medicines and cost-effectivenessClinicoEconomics and Outcomes Research, 2011
- Biosimilar agents in oncology/haematology: from approval to practiceEuropean Journal of Haematology, 2010
- Quality of Original and Biosimilar Epoetin ProductsPharmaceutical Research, 2010
- Biosimilar therapeutics--what do we need to consider?NDT Plus, 2009
- Epoetin‐associated pure red cell aplasia: past, present, and future considerationsTransfusion, 2008
- The challenge of biosimilarsAnnals Of Oncology, 2007